Barclays PLC Raises Holdings in XBiotech Inc. (NASDAQ:XBIT)

Barclays PLC increased its stake in shares of XBiotech Inc. (NASDAQ:XBIT) by 13.9% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 30,004 shares of the biopharmaceutical company’s stock after acquiring an additional 3,661 shares during the period. Barclays PLC’s holdings in XBiotech were worth $119,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently bought and sold shares of the company. JPMorgan Chase & Co. boosted its position in shares of XBiotech by 68.2% in the 4th quarter. JPMorgan Chase & Co. now owns 14,624 shares of the biopharmaceutical company’s stock worth $58,000 after buying an additional 5,930 shares in the last quarter. Virtu Financial LLC acquired a new position in XBiotech in the fourth quarter valued at $58,000. Bank of New York Mellon Corp grew its holdings in XBiotech by 7.5% in the fourth quarter. Bank of New York Mellon Corp now owns 91,060 shares of the biopharmaceutical company’s stock valued at $360,000 after purchasing an additional 6,328 shares during the period. Finally, Jane Street Group LLC purchased a new position in shares of XBiotech in the 3rd quarter worth $86,000. 55.70% of the stock is owned by institutional investors and hedge funds.

XBiotech Trading Down 3.4%

NASDAQ:XBIT opened at $2.88 on Thursday. XBiotech Inc. has a twelve month low of $2.65 and a twelve month high of $9.05. The firm has a market capitalization of $87.81 million, a price-to-earnings ratio of -2.67 and a beta of 0.98. The firm’s fifty day simple moving average is $3.10 and its 200 day simple moving average is $4.36.

XBiotech (NASDAQ:XBIT) last released its earnings results on Wednesday, May 14th. The biopharmaceutical company reported ($0.36) earnings per share for the quarter.

About XBiotech

XBiotech Inc, a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation.